| [1] |
谢院生. 药源性肾损害的诊治与预防[J/CD]. 中华肾病研究电子杂志，2021, 10(2): 120.
|
| [2] |
Nunes LLA, Lima TM. Use of medicines for covid-19 treatment in patients with loss of kidney function: a narrative review [J]. J Bras Nefrol, 2021, 43(2): 254-262.
|
| [3] |
Ng JH, Bijol V, Sparks MA, et al. Pathophysiology and pathology of acute kidney injury in patients with COVID-19 [J]. Adv Chronic Kidney Dis, 2020, 27(5): 365-376.
|
| [4] |
Palevsky PM. COVID-19 and AKI: where do we stand? [J]. J Am Soc Nephrol, 2021, 32(5): 1029-1032.
|
| [5] |
Jonny J, Violetta L, Kartasasmita AS, et al. Pharmacological treatment options for coronavirus disease-19 in renal patients [J]. Int J Nephrol, 2021, 2021: 4078713.
|
| [6] |
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report [J]. N Engl J Med, 2020, 383(19): 1813-1826.
|
| [7] |
Mahase E. Covid-19: Pfizer′s paxlovid is 89% effective in patients at risk of serious illness, company reports [J]. BMJ, 2021, 375: n2713.
|
| [8] |
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients [J]. N Engl J Med, 2022, 386(6): 509-520.
|
| [9] |
Pettit NN, Pisano J, Nguyen CT, et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? [J]. Clin Infect Dis, 2021, 73(11): e3990-e3995.
|
| [10] |
Chouchana L, Preta LH, Tisseyre M, et al. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study [J]. Kidney Int, 2021, 99(5): 1235-1236.
|
| [11] |
Gerard AO, Laurain A, Fresse A, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database [J]. Clin Pharmacol Ther, 2021, 109(4): 1021-1024.
|
| [12] |
Silva NAO, Zara A, Figueras A, et al. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database [J]. Cad Saude Publica, 2021, 37(10): e00077721.
|
| [13] |
Abdelbary AA, Alharafsheh AE, Ahmed A, et al. Favipiravir-induced nephrotoxicity in a patient with COVID-19: a case report [J]. Clin Case Rep, 2021, 9(8): e04539.
|
| [14] |
Binois Y, Hachad H, Salem JE, et al. Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with COVID-19 [J]. Kidney Int Rep, 2020, 5(10): 1787-1790.
|
| [15] |
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 [J]. N Engl J Med, 2020, 382(19): 1787-1799.
|
| [16] |
Arrestier R, Stehle T, Letavernier E, et al. Lopinavir-ritonavir associated acute kidney injury is not related to crystalluria in critically ill COVID-19 patients [J]. Kidney Int Rep, 2020, 5(11): 2119.
|
| [17] |
Schneider J, Jaenigen B, Wagner D, et al. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients [J]. PLoS One, 2021, 16(5): e0249760.
|
| [18] |
Prikis M, Cameron A. Paxlovid (nirmatelvir/ritonavir) and tacrolimus dug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report [J]. Transplant Proc, 2022, 54(6): 1557-1560.
|
| [19] |
Yücel HE. A case of acute renal failure with COVID-19 under molnupiravir treatment [J]. Med Sci Discov, 2022, 9(6): 371-374.
|
| [20] |
Nasa P, Shrivastava P, Kulkarni A, et al. Favipiravir induced nephrotoxicity in two patients of COVID-19 [J]. J Assoc Physicians India, 2021, 69(1): 90.
|
| [21] |
Launay M, Demartin AL, Ragey SP, et al. Severe inflammation, acute kidney injury, and drug-drug interaction: triple penalty for prolonged elimination of apixaban in patients with coronavirus disease 2019: a grand round [J]. Ther Drug Monit, 2021, 43(4): 455-458.
|
| [22] |
Dhampalwar S, Saigal S, Soin AS. Treatment armamentarium of COVID-19: evolving strategies and evidence so far [J]. J Clin Exp Hepatol, 2020, 10(6): 599-609.
|
| [23] |
Hashemian SMR, Pourhanifeh MH, Hamblin MR, et al. RdRp inhibitors and COVID-19: is molnupiravir a good option? [J]. Biomed Pharmacother, 2022, 146: 112517.
|
| [24] |
Leowattana W. Antiviral drugs and acute kidney injury (AKI) [J]. Infect Disord Drug Targets, 2019, 19(4): 375-382.
|
| [25] |
Soto K, Campos P, Manso R, et al. Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy [J]. Kidney Int Rep, 2019, 4(3): 494-499.
|
| [26] |
Novick TK, Choi MJ, Rosenberg AZ, et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report [J]. Medicine (Baltimore), 2017, 96(36): e8046.
|
| [27] |
Deiva A, Jayaprakash V, Jose N, et al. Acute kidney injury in a patient treated with tenofovir alafenamide fumarate for hepatitis B virus infection [J]. Saudi J Kidney Dis Transpl, 2021, 32(2): 592-594.
|
| [28] |
Ueaphongsukkit T, Gatechompol S, Avihingsanon A, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review [J]. AIDS Res Ther, 2021, 18(1): 53.
|
| [29] |
Bernhoff E, Gutteberg TJ, Sandvik K, et al. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression [J]. Am J Transplant, 2008, 8(7): 1413-1422.
|
| [30] |
Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure [J]. Clin Infect Dis, 1999, 29(4): 948-949.
|
| [31] |
Zhou Y, Wei M, Zhang M, et al. Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis [J]. Toxicol Lett, 2022, 359: 10-21.
|
| [32] |
Chavez-Iniguez JS, Medina-Gonzalez R, Aguilar-Parra L, et al. Oral acyclovir induced hypokalemia and acute tubular necrosis a case report [J]. BMC Nephrol, 2018, 19(1): 324.
|
| [33] |
Giustina A, Romanelli G, Cimino A, et al. Low-dose acyclovir and acute renal failure [J]. Ann Intern Med, 1988, 108(2): 312.
|
| [34] |
Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection [J]. Drugs, 1999, 58(6): 1165-1203.
|
| [35] |
Lodi L, Mastrolia MV, Bello F, et al. Type I interferon-related kidney disorders [J]. Kidney Int, 2022, 101(6): 1142-1159.
|
| [36] |
Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney [J]. Clin J Am Soc Nephrol, 2018, 13(2): 300-317.
|
| [37] |
Allinovi M, Cirami CL, Caroti L, et al. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab [J]. Clin Kidney J, 2017, 10(5): 625-631.
|